Current and future molecular diagnostics in non-small-cell lung cancer

Chun Man Li, Wing Ying Chu, Di Lun Wong, Hin Fung Tsang, Nancy Bo Yin Tsui, Charles Ming Lok Chan, Vivian Wei Wen Xue, Parco Ming Fai Siu, Yat Ming Yung, Wing Chi Chan, Sze Chuen Cesar Wong

Research output: Journal article publicationReview articleAcademic researchpeer-review

13 Citations (Scopus)


The molecular investigation of lung cancer has opened up an advanced area for the diagnosis and therapeutic management of lung cancer patients. Gene alterations in cancer initiation and progression provide not only information on molecular changes in lung cancer but also opportunities in advanced therapeutic regime by personalized targeted therapy. EGFR mutations and ALK rearrangement are important predictive biomarkers for the efficiency of tyrosine kinase inhibitor treatment in lung cancer patients. Moreover, epigenetic aberration and microRNA dysregulation are recent advances in the early detection and monitoring of lung cancer. Although a wide range of molecular tests are available, standardization and validation of assay protocols are essential for the quality of the test outcome. In this review, current and new advancements of molecular biomarkers for non-small-cell lung cancer will be discussed. Recommendations on future development of molecular diagnostic services will also be explored.
Original languageEnglish
Pages (from-to)1061-1074
Number of pages14
JournalExpert Review of Molecular Diagnostics
Issue number8
Publication statusPublished - 1 Jan 2015


  • ALK rearrangement
  • EGFR mutation
  • molecular diagnostics
  • non-small-cell lung cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine
  • Molecular Biology
  • Genetics


Dive into the research topics of 'Current and future molecular diagnostics in non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this